{ "model": { "rank": 5881, "code": "thing-q186242", "model_id": "vr.tr.norepinephrine", "name": "norepinephrine", "purpose": "Enable an AI agent to recognise norepinephrine, interpret its measured or material state, and determine which handling, analytical or biological-use actions are supported by evidence.", "family": "Thing Registry", "category": "Physical world and living systems", "status": "research-draft", "kind": "thing", "plane": "PHY", "domain": "PHY.MAT", "industry": "", "version": "", "url": "/models/thing/q186242/", "tier": 2, "score": 64, "payload": { "layer": "wikidata", "aliases": [], "aliasCount": 0, "merged": 0, "knownIn": 64, "facets": null, "markers": [], "lexicalClass": "", "senseRank": null, "alsoRegisteredAs": null, "source": { "dataset": "wikidata", "item": "Q186242", "url": "https://www.wikidata.org/wiki/Q186242", "license": "CC0 1.0" } }, "research": { "vercy": "1.0-draft", "publication": { "status": "research-draft", "adjudicationStatus": "unreviewed", "publishableCanonical": false, "generatedAt": "2026-09-07T09:51:56Z", "providers": [ "Codex", "Grok" ], "missingProviders": [], "pass": 2, "cost": { "grok": { "usd": 0.0705699, "turns": 7, "seconds": 199.9, "error": null }, "codex": { "seconds": 92.7, "error": "Reading additional input from stdin...\nOpenAI Codex v0.153.3\n--------\nworkdir: R:\\02_PROJECTS\\02_Meta_Models_Platforms\\Ver.cy\\current\\thing-registry-backlog\nmodel: gpt-6-astra\nprovider: openai\napproval: never\nsandbox: read-only\nreasoning effort: none\nreasoning summaries: none\nsession id: 01a07b45-0994-77c3-b324-fc32ae5a8c54\n--------\nuser\nYou are drafting a Vercy meta-model for one registered thing. Answer as JSON only, no prose around it.\n\nThing: norepinephrine\nRegistry id: vr.tr.norepinephrine\nPlane / domain: PHY / PHY.MAT\nRegistry definition: (none recorded)\nNames folded into this entry: (no" } } }, "metaModel": { "id": "THING-Q186242", "registryId": "vr.tr.norepinephrine", "name": "norepinephrine", "version": "0.1.0-research.1", "entryKind": "thing", "family": "Thing Registry", "domain": [ "PHY.MAT" ], "status": "research-draft" }, "canonicalUrl": "https://ver.cy/models/thing/q186242/", "model": { "registry_id": "vr.tr.norepinephrine", "name": "norepinephrine", "purpose": "Enable an AI agent to recognise norepinephrine, interpret its measured or material state, and determine which handling, analytical or biological-use actions are supported by evidence.", "definition": "Norepinephrine is the (R)-catecholamine 4-[(1R)-2-amino-1-hydroxyethyl]benzene-1,2-diol that is the principal transmitter of postganglionic sympathetic neurons and a secondary adrenal-medullary hormone, acting mainly at α1- and β1-adrenoceptors.", "scope_statement": "This model owns vr.tr.norepinephrine as a chemical substance and the norepinephrine-specific identity, quantity, integrity and biological-context evidence needed to assess its occurrences in specimens, reagents and medicinal preparations.", "in_scope": [ "Molecular identity, stereochemistry and recognition of the name noradrenaline without creating another registry entry.", "Distinction between norepinephrine active moiety, salt forms and formulations containing it.", "Norepinephrine amount, concentration, purity and analytical confidence.", "Chemical integrity and handling constraints for norepinephrine-containing material.", "Biological compartment, origin, exposure and links to observed activity." ], "out_of_scope": [ "Complete models of epinephrine, dopamine, metabolites or adrenergic receptors.", "Whole-organism sympathetic regulation, cognition and endocrine physiology.", "Diagnosis of diseases from catecholamine measurements.", "Patient-specific prescribing, infusion titration and emergency treatment protocols.", "Complete medicinal-product manufacturing, packaging and regulatory records." ], "distinguishing_features": [ "Require a molecular-structure match; norepinephrine has an unsubstituted amine nitrogen where epinephrine has an N-methyl substituent.", "Require the side-chain hydroxyl group that distinguishes norepinephrine from dopamine; a generic catecholamine signal is insufficient identification.", "Resolve stereochemistry explicitly: an opposite enantiomer or unresolved mixture must not silently inherit the identity and activity assumptions of the specified stereoisomer. See [PubChem norepinephrine](https://pubchem.ncbi.nlm.nih.gov/compound/439260) and [opposite enantiomer](https://pubchem.ncbi.nlm.nih.gov/compound/5814).", "Separate active-moiety identity from counterion and hydration state: a mass stated as norepinephrine base is not interchangeable with the same mass of its salt. See [DailyMed product label](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=dd4b7827-2fe9-4427-a40a-60f275611bf4).", "Require analytical discrimination from related catecholamines and metabolites; physiological effects or an ambiguous abbreviation alone do not establish norepinephrine identity." ], "characteristics": [ { "name": "Identity resolution", "kind": "state", "unit_or_values": "name-only | structure-linked | analytically-supported | conflicting", "why_it_matters": "Determines whether the agent can treat a record as norepinephrine rather than a provisional catecholamine identification." }, { "name": "Stereochemical specification", "kind": "category", "unit_or_values": "specified absolute configuration | racemate | quantified mixture | unresolved", "why_it_matters": "Prevents transfer of identity or activity evidence between stereochemically different materials." }, { "name": "Chemical presentation", "kind": "category", "unit_or_values": "free base | specified salt and hydration state | dissolved species in stated medium | unresolved", "why_it_matters": "Controls interpretation of material mass, composition and preparation instructions." }, { "name": "Norepinephrine quantity", "kind": "measurement", "unit_or_values": "mol, mass or concentration with explicit active-moiety versus salt basis; timed excretion as amount/time", "why_it_matters": "Makes quantities comparable without confusing concentration, total amount or salt mass." }, { "name": "Analytical uncertainty", "kind": "measurement", "unit_or_values": "method-specific uncertainty, detection limit and quantification limit in the result unit", "why_it_matters": "Distinguishes a credible result from a weak signal or a value below reliable quantification." }, { "name": "Material integrity", "kind": "state", "unit_or_values": "supported within specification | suspected degradation | confirmed out of specification | unassessed", "why_it_matters": "Prevents identity or nominal concentration from being mistaken for current fitness for use." }, { "name": "Biological or preparation context", "kind": "relation", "unit_or_values": "linked specimen, compartment, preparation, collection event and exposure history", "why_it_matters": "Locates the substance and limits what a measurement can imply about biological activity." }, { "name": "Origin assessment", "kind": "category", "unit_or_values": "endogenous | administered | laboratory-added | mixed | unknown", "why_it_matters": "Supports interpretation while acknowledging that molecular identity alone cannot establish origin." }, { "name": "Use eligibility", "kind": "state", "unit_or_values": "supported for specified use | conditional | withheld | undetermined", "why_it_matters": "Connects identity, quality and formulation evidence to a particular proposed action." } ], "affordances": [ "Resolve norepinephrine and noradrenaline mentions to this entry while flagging ambiguous abbreviations.", "Compare analytical identity evidence with a specified norepinephrine reference material.", "Normalize quantities to norepinephrine active-moiety equivalents when salt composition and hydration are established.", "Attach specimen and exposure context to a norepinephrine measurement without inferring a diagnosis.", "Assess whether storage and analytical evidence support continued use for a stated purpose.", "Route a proposed preparation or administration action to the applicable product and clinical protocol models." ] }, "sources": [ { "id": "statpearls-norepinephrine", "title": "Norepinephrine - StatPearls (NCBI Bookshelf / StatPearls Publishing)", "url": "https://www.ncbi.nlm.nih.gov/books/NBK537259/", "what_it_supports": "Transmitter and hormone roles; α1/β1 receptor profile versus epinephrine; FDA hypotensive-state indication; Surviving Sepsis first-line use; pharmacokinetics (half-life, Vd, protein binding, COMT/MAO metabolism); infusion practice and dextrose-diluent warning.", "url_status": "live" }, { "id": "pubchem-norepinephrine", "title": "Norepinephrine | C8H11NO3 | CID 439260 - PubChem (NCBI)", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/439260", "what_it_supports": "Molecular formula, IUPAC name, CAS 51-41-2, Wikidata Q186242, DrugBank DB00368, RxCUI 7512, HMDB0000216, and related registry identifiers.", "url_status": "live" }, { "id": "acs-motw-norepinephrine", "title": "Norepinephrine - Molecule of the Week (American Chemical Society)", "url": "https://www.acs.org/molecule-of-the-week/archive/n/norepinephrine.html", "what_it_supports": "INN versus BAN naming (norepinephrine vs noradrenaline); CAS 51-41-2; molar mass, melting point, water solubility; nor- prefix as N-demethyl epinephrine.", "url_status": "live" }, { "id": "cleveland-clinic-norepinephrine", "title": "Norepinephrine (Noradrenaline) - Cleveland Clinic", "url": "https://my.clevelandclinic.org/health/articles/22610-norepinephrine-noradrenaline", "what_it_supports": "Dual neurotransmitter/hormone role; synthesis from dopamine; clinical use to raise blood pressure; contrast with epinephrine's adrenal-hormone and anaphylaxis profile.", "url_status": "live" }, { "id": "uk-smpc-noradrenaline", "title": "Noradrenaline (Norepinephrine) 1 mg/ml Concentrate for Solution for Infusion - Summary of Product Characteristics (electronic Medicines Compendium / MHRA)", "url": "https://www.medicines.org.uk/emc/product/5353/smpc", "what_it_supports": "UK dual naming; tartrate-to-base equivalence (2 mg tartrate = 1 mg base); typical 40 mg/L base infusion; titration in µg/kg/min; central-line administration; ischaemia cautions.", "url_status": "live" }, { "id": "pfizer-levophed-uspi", "title": "LEVOPHED (norepinephrine bitartrate) injection, for intravenous use - U.S. prescribing information (Pfizer)", "url": "https://labeling.pfizer.com/ShowLabeling.aspx?id=20428", "what_it_supports": "U.S. approval 1950; indication for adult acute hypotensive states; α-vasoconstrictor plus β-inotropic/coronary actions; injectable pH 3.0-4.5; overdose management.", "url_status": "live" }, { "id": "ccf-labs-plasma-catecholamines", "title": "Catecholamines, Fractionated, Plasma - Cleveland Clinic Laboratories", "url": "https://clevelandcliniclabs.com/test/catecholamines-fractionated-plasma/", "what_it_supports": "Adult plasma norepinephrine reference intervals by posture; LC-MS/MS method; collection artefacts; preference for metanephrines over parent catecholamines in pheochromocytoma work-up.", "url_status": "unverified" }, { "id": "ajrccm-vasoactive-shock", "title": "Vasoactive Drugs in Circulatory Shock - American Journal of Respiratory and Critical Care Medicine (ATS Journals)", "url": "https://www.atsjournals.org/doi/10.1164/rccm.201006-0972CI", "what_it_supports": "Comparative receptor and haemodynamic profiles of norepinephrine versus dopamine, epinephrine, phenylephrine and vasopressin; argument for norepinephrine as first-line vasopressor in shock.", "url_status": "blocked" } ], "structure": { "bundles": [ { "id": "catecholamine-identity", "name": "Catecholamine identity", "description": "Establish whether the referent is norepinephrine and how precisely its molecular identity is known.", "rationale": "Related catecholamines, stereoisomers and abbreviated names can otherwise be conflated.", "layers": [ { "id": "molecular-discrimination", "name": "Molecular discrimination", "description": "Connect the name to discriminating structural and analytical evidence.", "findings": [ { "id": "norepinephrine-identity-evidence", "name": "Norepinephrine identity evidence", "description": "Record what supports norepinephrine identification and what alternatives the evidence excludes.", "questions": [ { "text": "Which structure-linked reference establishes that this referent is norepinephrine rather than epinephrine, dopamine or another catecholamine?", "kind": "definition", "id": "norepinephrine-identity-evidence-q01" }, { "text": "Which analytical observations distinguish norepinephrine from the related compounds present in this material?", "kind": "measurement", "id": "norepinephrine-identity-evidence-q02" } ] } ] }, { "id": "stereochemistry-and-naming", "name": "Stereochemistry and naming", "description": "Preserve stereochemical specificity and resolve names without duplicating the registered concept.", "findings": [ { "id": "stereochemical-reference", "name": "Stereochemical reference", "description": "Separate verified configuration from naming conventions and unresolved composition.", "questions": [ { "text": "Is absolute configuration or enantiomeric composition established, and by what evidence?", "kind": "measurement", "id": "stereochemical-reference-q01" }, { "text": "Does the source use norepinephrine, noradrenaline or an abbreviation for the same specified substance, or leave its identity ambiguous?", "kind": "boundary", "id": "stereochemical-reference-q02" } ] } ] } ] }, { "id": "chemical-form-and-quantity", "name": "Chemical form and quantity", "description": "Determine what norepinephrine-containing material is present and what its stated quantity counts.", "rationale": "Active-moiety, salt and formulation quantities can represent different amounts despite similar labels.", "layers": [ { "id": "active-moiety-and-salt", "name": "Active moiety and salt", "description": "Separate the norepinephrine component from counterions, water and formulation ingredients.", "findings": [ { "id": "presentation-resolution", "name": "Presentation resolution", "description": "Identify the chemical presentation needed to interpret composition and transformations.", "questions": [ { "text": "Is the material specified as norepinephrine free base, a named salt with known hydration, or norepinephrine in a stated solution?", "kind": "definition", "id": "presentation-resolution-q01" }, { "text": "Which label, certificate or analysis establishes counterion, stoichiometry and water basis?", "kind": "provenance", "id": "presentation-resolution-q02" } ] } ] }, { "id": "amount-basis", "name": "Amount basis", "description": "Make amounts and concentrations comparable while retaining their original meaning.", "findings": [ { "id": "active-moiety-equivalence", "name": "Active-moiety equivalence", "description": "Record the denominator, chemical basis and evidence supporting any quantity conversion.", "questions": [ { "text": "Does the reported value count norepinephrine active moiety, total salt mass, concentration in a matrix or amount collected over time?", "kind": "measurement", "id": "active-moiety-equivalence-q01" }, { "text": "Are composition, units and volume or collection interval sufficiently known to convert the value without assuming missing information?", "kind": "action", "id": "active-moiety-equivalence-q02" } ] } ] } ] }, { "id": "specimen-and-assay-interpretation", "name": "Specimen and assay interpretation", "description": "Establish what a norepinephrine measurement represents and how reliable it is.", "rationale": "A result depends on the sampled compartment, collection conditions and assay specificity.", "layers": [ { "id": "collection-context", "name": "Collection context", "description": "Bind a measurement to the specimen and the conditions under which it was obtained.", "findings": [ { "id": "sampled-norepinephrine", "name": "Sampled norepinephrine", "description": "Record the biological matrix or prepared medium and contextual factors required for comparison.", "questions": [ { "text": "Which matrix or compartment was sampled, at what time, and with what timed-collection basis if applicable?", "kind": "provenance", "id": "sampled-norepinephrine-q01" }, { "text": "Which collection, preservation, posture, activity and medication conditions does the applicable norepinephrine assay require the agent to retain?", "kind": "measurement", "id": "sampled-norepinephrine-q02" } ] } ] }, { "id": "analytical-validity", "name": "Analytical validity", "description": "Determine whether the assay supports the reported identity and quantity.", "findings": [ { "id": "assay-specific-confidence", "name": "Assay-specific confidence", "description": "Preserve calibration, interference, recovery and quantification evidence for norepinephrine.", "questions": [ { "text": "What calibration and quality-control evidence supports this norepinephrine result in this matrix?", "kind": "measurement", "id": "assay-specific-confidence-q01" }, { "text": "Were related catecholamines, metabolites and other method-specific interferences resolved, and is the result within the validated quantification range?", "kind": "measurement", "id": "assay-specific-confidence-q02" } ] } ] } ] }, { "id": "integrity-and-preparation", "name": "Integrity and preparation", "description": "Assess the current condition of norepinephrine material and the evidence governing its preparation.", "rationale": "Nominal identity and labelled concentration do not establish retained potency or suitability after handling.", "layers": [ { "id": "stability-evidence", "name": "Stability evidence", "description": "Relate exposure history to formulation-specific integrity criteria.", "findings": [ { "id": "retained-norepinephrine", "name": "Retained norepinephrine", "description": "Assess degradation using applicable evidence rather than a universal shelf-life assumption.", "questions": [ { "text": "What temperature, light, oxygen, pH and elapsed-time history is known for this norepinephrine material?", "kind": "provenance", "id": "retained-norepinephrine-q01" }, { "text": "Which applicable stability data, appearance criteria and potency or impurity measurements support its present integrity?", "kind": "measurement", "id": "retained-norepinephrine-q02" } ] } ] }, { "id": "preparation-compatibility", "name": "Preparation compatibility", "description": "Connect intended dilution, mixing and transfer to evidence for the actual preparation.", "findings": [ { "id": "supported-preparation-action", "name": "Supported preparation action", "description": "Specify whether a proposed manipulation is supported for this concentration, medium and container.", "questions": [ { "text": "Which product-specific or validated laboratory evidence supports the proposed diluent, concentration, container and contact duration?", "kind": "action", "id": "supported-preparation-action-q01" }, { "text": "What missing compatibility or integrity evidence requires withholding the proposed preparation step?", "kind": "boundary", "id": "supported-preparation-action-q02" } ] } ] } ] }, { "id": "biological-role-and-use", "name": "Biological role and use", "description": "Connect norepinephrine occurrence to biological context and appropriately bounded use decisions.", "rationale": "The same chemical identity can occur in endogenous signalling, administered exposure or laboratory material.", "layers": [ { "id": "origin-and-activity-context", "name": "Origin and activity context", "description": "Locate norepinephrine in a biological setting without treating a concentration as a complete account of signalling.", "findings": [ { "id": "contextualized-occurrence", "name": "Contextualized occurrence", "description": "Separate observed presence, inferred origin and evidence of biological activity.", "questions": [ { "text": "What evidence supports endogenous, administered, laboratory-added or mixed origin for this norepinephrine occurrence?", "kind": "provenance", "id": "contextualized-occurrence-q01" }, { "text": "Which compartment, exposure timing and receptor or response observations support a claim of activity, and what remains unmeasured?", "kind": "boundary", "id": "contextualized-occurrence-q02" } ] } ] }, { "id": "use-specific-eligibility", "name": "Use-specific eligibility", "description": "Determine which proposed uses the material evidence supports and which require neighbouring models.", "findings": [ { "id": "norepinephrine-use-boundary", "name": "Norepinephrine use boundary", "description": "Keep reagent identity, medicinal-product suitability and patient-specific decisions distinct.", "questions": [ { "text": "Does the evidence establish suitability as an analytical standard, research reagent or component of the specified medicinal preparation?", "kind": "action", "id": "norepinephrine-use-boundary-q01" }, { "text": "Which linked product and clinical protocol records must govern route, administration, monitoring and response to adverse exposure?", "kind": "boundary", "id": "norepinephrine-use-boundary-q02" } ] } ] } ] }, { "id": "evidence-and-external-alignment", "name": "Evidence and external alignment", "description": "What the world already says about this thing, gathered so the model can be checked against it.", "rationale": "A model that cannot be lined up against existing standards, identifiers and practice cannot be adopted by anyone who already uses them.", "layers": [ { "id": "reported-evidence", "name": "Reported evidence", "description": "Findings from the breadth pass, kept separate from the structural claims.", "findings": [ { "id": "evidence-kinds", "name": "Kinds and varieties", "description": "Reported by the breadth pass; each item needs checking against its source before it becomes normative.", "evidence": [ "Peripheral sympathetic neurotransmitter released from postganglionic noradrenergic terminals", "Central noradrenergic neurotransmitter of locus coeruleus and related brainstem nuclei", "Circulating hormone secreted by adrenal-medullary chromaffin cells", "Intravenous vasopressor drug (norepinephrine/noradrenaline infusion, e.g. Levophed)", "(R)-L-norepinephrine, the endogenous and pharmaceutical enantiomer, versus racemic or (S) material", "Pharmaceutical salts: bitartrate/tartrate injection versus hydrochloride", "Clinical laboratory analyte (plasma or urine free norepinephrine in a fractionated catecholamine panel)" ], "questions": [ { "id": "evidence-kinds-q01", "text": "Which of these kinds and varieties hold for the sense of norepinephrine this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-identifiers", "name": "Identifiers and schemes", "description": "Reported by the breadth pass; each item needs checking against its source before it becomes normative.", "evidence": [ { "scheme": "Wikidata", "value_or_pattern": "Q186242", "note": "Wikidata item for norepinephrine." }, { "scheme": "CAS Registry Number", "value_or_pattern": "51-41-2", "note": "L-(R)-norepinephrine free base; racemate is 138-65-8; l-tartrate (1:1) is 51-40-1." }, { "scheme": "PubChem CID", "value_or_pattern": "439260", "note": "Compound record for (R)-norepinephrine." }, { "scheme": "INN (WHO)", "value_or_pattern": "norepinephrine", "note": "International Nonproprietary Name; Latin norepinephrinum, Spanish norepinefrina." }, { "scheme": "BAN", "value_or_pattern": "noradrenaline", "note": "British Approved Name, still used in UK/Commonwealth product names." }, { "scheme": "DrugBank", "value_or_pattern": "DB00368", "note": "Drug record for the pharmaceutical substance." }, { "scheme": "RxNorm RXCUI", "value_or_pattern": "7512", "note": "NLM RxNorm concept for norepinephrine." }, { "scheme": "ATC", "value_or_pattern": "C01CA03", "note": "WHO ATC code: cardiac stimulants excl. cardiac glycosides, adrenergic and dopaminergic agents." }, { "scheme": "HMDB", "value_or_pattern": "HMDB0000216", "note": "Human Metabolome Database entry." }, { "scheme": "EPA DSSTox", "value_or_pattern": "DTXSID5023378", "note": "CompTox substance identifier." }, { "scheme": "IUPAC name", "value_or_pattern": "4-[(1R)-2-amino-1-hydroxyethyl]benzene-1,2-diol", "note": "Preferred IUPAC name of the endogenous enantiomer; formula C8H11NO3." } ], "questions": [ { "id": "evidence-identifiers-q01", "text": "Which of these identifiers and schemes hold for the sense of norepinephrine this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-standards-and-regulation", "name": "Standards and regulation", "description": "Reported by the breadth pass; each item needs checking against its source before it becomes normative.", "evidence": [ "U.S. FDA - LEVOPHED (norepinephrine bitartrate) injection, initial approval 1950, indicated to restore blood pressure in adult acute hypotensive states; labeling requires dilution in dextrose-containing solutions and warns against saline as the sole diluent.", "WHO INN Programme - recommended international nonproprietary name norepinephrine (distinct from the BAN noradrenaline).", "MHRA / UK SmPC - licensed noradrenaline (norepinephrine) tartrate concentrate for emergency restoration of blood pressure in acute hypotension; specifies tartrate-to-base equivalence and controlled-rate infusion.", "Surviving Sepsis Campaign (SCCM / ESICM) - norepinephrine as first-line vasopressor for septic shock that remains hypotensive after fluid resuscitation.", "UN GHS - ACS records GHS hazard classification for the neat chemical (laboratory handling), separate from the sterile injectable monograph." ], "questions": [ { "id": "evidence-standards-and-regulation-q01", "text": "Which of these standards and regulation hold for the sense of norepinephrine this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-real-world-use", "name": "Real-world use", "description": "Reported by the breadth pass; each item needs checking against its source before it becomes normative.", "evidence": [ "First-line continuous intravenous vasopressor in ICU septic shock after fluids, titrated to a mean arterial pressure target (commonly ≥65 mmHg).", "Short-term restoration of blood pressure in other acute hypotensive states, including some cardiogenic, neurogenic and anaesthetic hypotensions.", "Hospital product as 1 mg/mL base concentrate (2 mg/mL tartrate), typically diluted to about 40 mg/L base and given by syringe or infusion pump, preferably via a central venous catheter.", "Endogenous mediator of sympathetic vasoconstriction, alertness and the acute stress (fight-or-flight) response.", "Plasma or urine fractionated catecholamine assay (LC-MS/MS) when excess sympathetic secretion is suspected; plasma free metanephrines are preferred for pheochromocytoma.", "Pharmacologic target of SNRIs, selective norepinephrine reuptake inhibitors and MAO inhibitors used in depression, anxiety and some pain syndromes - those drugs are not norepinephrine itself." ], "questions": [ { "id": "evidence-real-world-use-q01", "text": "Which of these real-world use hold for the sense of norepinephrine this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-measurements", "name": "Typical measurements", "description": "Reported by the breadth pass; each item needs checking against its source before it becomes normative.", "evidence": [ { "quantity": "molar mass", "typical_range": "169.18", "unit": "g/mol" }, { "quantity": "plasma norepinephrine, adult seated 15 min", "typical_range": "1050-4800", "unit": "pmol/L" }, { "quantity": "plasma norepinephrine, adult supine 30 min", "typical_range": "680-3100", "unit": "pmol/L" }, { "quantity": "plasma elimination half-life", "typical_range": "about 2.4", "unit": "min" }, { "quantity": "adult IV infusion, initial non-weight-based rate", "typical_range": "8-12 to start, then titrated (usual reported ranges on the order of 2-40)", "unit": "µg/min as base" }, { "quantity": "adult IV infusion, weight-based maintenance", "typical_range": "0.05-0.5 typical; titration steps 0.05-0.1; high-dose/refractory use may exceed 1", "unit": "µg/kg/min as base" }, { "quantity": "prepared infusion concentration (UK SmPC usual dilution)", "typical_range": "40 as base (80 as tartrate)", "unit": "mg/L" }, { "quantity": "apparent volume of distribution / plasma protein binding", "typical_range": "8.8 L; about 25% bound", "unit": "L ; %" }, { "quantity": "melting point (free base, decomposes) / water solubility", "typical_range": "217 (dec.); 0.85", "unit": "°C ; g/L" }, { "quantity": "injectable solution pH", "typical_range": "3.0-4.5", "unit": "pH" } ], "questions": [ { "id": "evidence-measurements-q01", "text": "Which of these typical measurements hold for the sense of norepinephrine this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-failure-modes-and-hazards", "name": "Failure modes and hazards", "description": "Reported by the breadth pass; each item needs checking against its source before it becomes normative.", "evidence": [ "Extravasation of the infusion causes intense local vasoconstriction and tissue ischaemia or necrosis; phentolamine is the usual local antidote where available.", "Excess α-adrenergic constriction can worsen coronary, mesenteric or peripheral ischaemia and extend thrombosis; product information warns in patients with existing vascular thrombosis.", "β1 stimulation can provoke tachyarrhythmia or atrial fibrillation; baroreflex from the pressure rise may instead produce reflex bradycardia.", "Catechol oxidation: potency is lost on air/light exposure and, per FDA labeling, if saline is used as the sole diluent rather than a dextrose-containing solution.", "Overdose produces severe hypertension; the labeled response is to stop the infusion until the patient restabilises.", "Peripheral (non-CNS) administration does not treat central noradrenergic deficiency because norepinephrine does not cross the blood-brain barrier.", "Some formulations contain metabisulfite, a hypersensitivity hazard distinct from the catecholamine itself.", "High-dose 'refractory' shock: further dose escalation may fail to restore perfusion and is a cue to add another vasopressor or revisit the cause rather than treat the molecule as infinitely titratable." ], "questions": [ { "id": "evidence-failure-modes-and-hazards-q01", "text": "Which of these failure modes and hazards hold for the sense of norepinephrine this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-regional-variation", "name": "Regional variation", "description": "Reported by the breadth pass; each item needs checking against its source before it becomes normative.", "evidence": [ "United States and WHO INN use norepinephrine; United Kingdom and many Commonwealth labels use noradrenaline, often as the dual name 'noradrenaline (norepinephrine)'.", "Laboratory and physiology abbreviations split the same way: NE in much US literature, NA in much European literature.", "Brand and synonym geography: Levophed is the widely recognised US trade name; Arterenol appears in German use; other local names include Adrenor.", "Diluent practice is not uniform: FDA labeling rejects saline as the sole diluent, while some European product information and bedside practice still prepare infusions in 0.9% sodium chloride as well as glucose 5%.", "Chinese clinical short names include 去甲肾上腺素 (and colloquial 去甲肾); Spanish INN is norepinefrina, Italian noradrenalina." ], "questions": [ { "id": "evidence-regional-variation-q01", "text": "Which of these regional variation hold for the sense of norepinephrine this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-neighbours", "name": "Neighbouring kinds and how to tell them apart", "description": "Reported by the breadth pass; each item needs checking against its source before it becomes normative.", "evidence": [ { "name": "epinephrine (adrenaline)", "difference": "Epinephrine is the N-methyl analogue with substantial β2 activity (bronchodilation, some vasodilation) and is first-line for anaphylaxis; norepinephrine lacks meaningful β2 action and is used for vasoconstrictor support of blood pressure. Fractionated catecholamine assay or the presence/absence of the N-methyl group on the structure separates them." }, { "name": "dopamine", "difference": "Dopamine is the biosynthetic precursor (dopamine β-hydroxylase adds the β-OH). Clinically it has dose-dependent dopaminergic then β then α effects and more tachyarrhythmia; comparative shock trials (e.g. SOAP II, as discussed in vasopressor reviews) favour norepinephrine as first-line vasopressor." }, { "name": "phenylephrine", "difference": "Phenylephrine is a pure α1 agonist without β1 inotropy, so blood pressure rises while cardiac output often falls and reflex bradycardia is common; norepinephrine retains some β1 support of contractility. Receptor-selectivity tables and the CO response distinguish them." }, { "name": "vasopressin", "difference": "Vasopressin is a V1-receptor peptide vasopressor, not a catecholamine, and is used as an adjunct rather than a substitute with the same receptor map; it is not a substrate of COMT/MAO in the catecholamine pathway." }, { "name": "normetanephrine", "difference": "Normetanephrine is the COMT O-methyl metabolite. Plasma free metanephrines are the preferred pheochromocytoma markers because parent norepinephrine is highly posture- and stress-sensitive; the laboratory menu (metanephrines vs fractionated catecholamines) is the practical test." }, { "name": "isoproterenol", "difference": "Isoproterenol is a non-selective β agonist that increases heart rate and contractility while lowering vascular resistance; norepinephrine's dominant clinical effect is α-mediated vasoconstriction with little β2 vasodilation." } ], "questions": [ { "id": "evidence-neighbours-q01", "text": "Which of these neighbouring kinds and how to tell them apart hold for the sense of norepinephrine this model covers, and on what evidence?", "kind": "provenance" } ] } ] } ] } ] }, "openQuestions": [ "Does an existing Vercy world model already own this concept, and should this registry entry link to that publication?", "Does the registry intend norepinephrine to identify a particular stereoisomer or a broader stereochemically unspecified substance, and how should salt presentations link to neighbouring models?", "Which authoritative analytical methods and specimen-specific interpretation criteria should this model support first?", "Which formulation-specific stability, degradation and compatibility evidence can support actionable integrity assessments across laboratory and medicinal contexts?", "What evidence is sufficient to distinguish endogenous from administered norepinephrine in each intended use context when both may contribute to a measurement?" ], "statistics": { "bundles": 6, "layers": 11, "findings": 18, "questions": 28 } }, "draft": { "generator": "vr.draft.v3", "status": "draft-generated", "researched": false, "archetype": "chemical substance or material", "method": "Written from the archetype playbook - what this kind of thing needs beyond identity and provenance - and from the structure that recurred across 6,333 models already researched by two engines. Applied to this entry by rule. No source was read for this thing and no claim here is researched. This entry carries no facets of its own, so they were inferred from its domain - a guess about a whole domain applied to one thing.", "facetsInferred": true, "nextPass": "A researcher replaces this draft with a sourced specification. Treat every sentence below as a proposal to argue with.", "purpose": "Give an agent a durable, checkable way to recognise a norepinephrine, record what state it is in, and decide what may be done with it.", "whatItIs": "Enable an AI agent to recognise norepinephrine, interpret its measured or material state, and determine which handling, analytical or biological-use actions are supported by evidence.", "characteristics": { "substance": "material", "origin": "natural", "agency": "inert", "mobility": "varies" }, "whatYouCanDoWithIt": [ "observed and measured", "consumed or used up" ], "distinguishingFeatures": [ "Described in 64 Wikipedia languages, which is a measure of how widely the thing is known, not of how important it is." ], "openQuestionsForResearch": [ "Which of the bundles below does a real task actually need, and which are ceremony?", "What does this thing have that the facets do not capture at all?", "Which neighbouring kind is most often confused with a norepinephrine, and on what evidence are they told apart?" ], "whatItIsMadeOf": "matter you can touch", "physicalCharacter": [ "Mobility varies between examples.", "Does nothing on its own; everything it does, something else did to it.", "These come from the domain this entry sits in rather than from the entry itself, so treat them as a first guess about the whole domain applied to one thing." ], "whatCanBeDoneWithIt": [ "observe it, measure it, record its state", "use it up, and then need more of it" ], "howItIsRecognised": [ "Not recognisable by sight in any reliable way. Appearance varies with grade, form and additives; identification is by label, by documentation, or by assay." ], "relatedModels": [], "standing": "Described in 64 Wikipedia languages, which measures how widely it is written about rather than how important or how common it is.", "structure": { "bundles": [ { "id": "identity-and-classification", "name": "Identity, naming and classification", "description": "How an agent tells one norepinephrine from another, and a norepinephrine from things that resemble it.", "rationale": "Recognition comes before every other claim. Without stable identity nothing else in the model can be trusted to be about the same thing twice.", "layers": [ { "id": "naming-and-identifiers", "name": "Names and identifiers", "description": "The names this thing goes by and the identifiers that survive translation and time.", "findings": [ { "id": "preferred-name-and-aliases", "name": "Preferred name, aliases and local names", "description": "Which name to use, which names mean the same thing, and which merely sound similar.", "questions": [ { "id": "preferred-name-and-aliases-q01", "text": "What identifies and describes the name of a norepinephrine, and in what units or vocabulary?", "kind": "definition", "answer_data": [ "identifiers", "types and classes", "values with units", "explicit unknowns" ] }, { "id": "preferred-name-and-aliases-q02", "text": "Who or what asserted this about the name of a norepinephrine, by which method, and when was it true?", "kind": "provenance", "answer_data": [ "authority", "method", "evidence", "event time", "knowledge time" ] }, { "id": "preferred-name-and-aliases-q03", "text": "What may an agent decide or do once the name of a norepinephrine is known, and what must it refuse?", "kind": "action", "answer_data": [ "permitted actions", "preconditions", "refusals", "escalation" ] } ] }, { "id": "stable-identifiers", "name": "Stable identifiers and external keys", "description": "Identifiers that keep pointing at this kind of thing across systems and languages.", "questions": [ { "id": "stable-identifiers-q01", "text": "What identifies and describes an identifier for a norepinephrine, and in what units or vocabulary?", "kind": "definition", "answer_data": [ "identifiers", "types and classes", "values with units", "explicit unknowns" ] }, { "id": "stable-identifiers-q02", "text": "Who or what asserted this about an identifier for a norepinephrine, by which method, and when was it true?", "kind": "provenance", "answer_data": [ "authority", "method", "evidence", "event time", "knowledge time" ] }, { "id": "stable-identifiers-q03", "text": "What may an agent decide or do once an identifier for a norepinephrine is known, and what must it refuse?", "kind": "action", "answer_data": [ "permitted actions", "preconditions", "refusals", "escalation" ] } ] } ] }, { "id": "classification-and-granularity", "name": "Classification and granularity", "description": "Where a norepinephrine sits among kinds, and how finely a task needs to cut it.", "findings": [ { "id": "kind-and-parents", "name": "Kind, parents and neighbouring kinds", "description": "The classes this thing belongs to and the ones it is next to.", "questions": [ { "id": "kind-and-parents-q01", "text": "What identifies and describes the kind of a norepinephrine, and in what units or vocabulary?", "kind": "definition", "answer_data": [ "identifiers", "types and classes", "values with units", "explicit unknowns" ] }, { "id": "kind-and-parents-q02", "text": "Who or what asserted this about the kind of a norepinephrine, by which method, and when was it true?", "kind": "provenance", "answer_data": [ "authority", "method", "evidence", "event time", "knowledge time" ] }, { "id": "kind-and-parents-q03", "text": "What may an agent decide or do once the kind of a norepinephrine is known, and what must it refuse?", "kind": "action", "answer_data": [ "permitted actions", "preconditions", "refusals", "escalation" ] } ] }, { "id": "distinguishing-features", "name": "Distinguishing features", "description": "What separates a norepinephrine from the things most often confused with it.", "questions": [ { "id": "distinguishing-features-q01", "text": "What identifies and describes what distinguishes a norepinephrine, and in what units or vocabulary?", "kind": "definition", "answer_data": [ "identifiers", "types and classes", "values with units", "explicit unknowns" ] }, { "id": "distinguishing-features-q02", "text": "Who or what asserted this about what distinguishes a norepinephrine, by which method, and when was it true?", "kind": "provenance", "answer_data": [ "authority", "method", "evidence", "event time", "knowledge time" ] }, { "id": "distinguishing-features-q03", "text": "What may an agent decide or do once what distinguishes a norepinephrine is known, and what must it refuse?", "kind": "action", "answer_data": [ "permitted actions", "preconditions", "refusals", "escalation" ] } ] } ] } ] }, { "id": "form-and-composition", "name": "Form, composition and condition", "description": "What a norepinephrine is made of, what shape and size it takes, and what state it is in.", "rationale": "A physical thing can be measured, and a model that cannot record its measurements cannot support any decision that depends on them.", "layers": [ { "id": "form-and-dimensions", "name": "Form and dimensions", "description": "Shape, size, mass and the ranges these take across examples.", "findings": [ { "id": "measurable-dimensions", "name": "Measurable dimensions and their units", "description": "The quantities worth recording and the units they are recorded in.", "questions": [ { "id": "measurable-dimensions-q01", "text": "What identifies and describes the dimensions of a norepinephrine, and in what units or vocabulary?", "kind": "definition", "answer_data": [ "identifiers", "types and classes", "values with units", "explicit unknowns" ] }, { "id": "measurable-dimensions-q02", "text": "Who or what asserted this about the dimensions of a norepinephrine, by which method, and when was it true?", "kind": "provenance", "answer_data": [ "authority", "method", "evidence", "event time", "knowledge time" ] }, { "id": "measurable-dimensions-q03", "text": "What may an agent decide or do once the dimensions of a norepinephrine is known, and what must it refuse?", "kind": "action", "answer_data": [ "permitted actions", "preconditions", "refusals", "escalation" ] } ] } ] }, { "id": "material-and-composition", "name": "Material and composition", "description": "Materials, parts and how they are put together.", "findings": [ { "id": "parts-and-materials", "name": "Parts and materials", "description": "What a norepinephrine is built from and which parts are replaceable.", "questions": [ { "id": "parts-and-materials-q01", "text": "What identifies and describes the composition of a norepinephrine, and in what units or vocabulary?", "kind": "definition", "answer_data": [ "identifiers", "types and classes", "values with units", "explicit unknowns" ] }, { "id": "parts-and-materials-q02", "text": "Who or what asserted this about the composition of a norepinephrine, by which method, and when was it true?", "kind": "provenance", "answer_data": [ "authority", "method", "evidence", "event time", "knowledge time" ] }, { "id": "parts-and-materials-q03", "text": "What may an agent decide or do once the composition of a norepinephrine is known, and what must it refuse?", "kind": "action", "answer_data": [ "permitted actions", "preconditions", "refusals", "escalation" ] } ] } ] }, { "id": "condition-and-integrity", "name": "Condition and integrity", "description": "Wear, damage, health and the difference between working and broken.", "findings": [ { "id": "condition-assessment", "name": "Condition, damage and health", "description": "How the condition of a norepinephrine is judged and by whom.", "questions": [ { "id": "condition-assessment-q01", "text": "What identifies and describes the condition of a norepinephrine, and in what units or vocabulary?", "kind": "definition", "answer_data": [ "identifiers", "types and classes", "values with units", "explicit unknowns" ] }, { "id": "condition-assessment-q02", "text": "Who or what asserted this about the condition of a norepinephrine, by which method, and when was it true?", "kind": "provenance", "answer_data": [ "authority", "method", "evidence", "event time", "knowledge time" ] }, { "id": "condition-assessment-q03", "text": "What may an agent decide or do once the condition of a norepinephrine is known, and what must it refuse?", "kind": "action", "answer_data": [ "permitted actions", "preconditions", "refusals", "escalation" ] } ] } ] } ] }, { "id": "place-and-movement", "name": "Place and movement", "description": "Where a norepinephrine is, how it got there and where it may go (varies).", "rationale": "A thing that can move needs its position recorded with a time, or every later claim about it is about a place it has left.", "layers": [ { "id": "location-and-placement", "name": "Location and placement", "description": "Position, containment and the reference frame the position is given in.", "findings": [ { "id": "position-and-frame", "name": "Position, container and reference frame", "description": "Where a norepinephrine is, and what that position is measured against.", "questions": [ { "id": "position-and-frame-q01", "text": "What identifies and describes the location of a norepinephrine, and in what units or vocabulary?", "kind": "definition", "answer_data": [ "identifiers", "types and classes", "values with units", "explicit unknowns" ] }, { "id": "position-and-frame-q02", "text": "Who or what asserted this about the location of a norepinephrine, by which method, and when was it true?", "kind": "provenance", "answer_data": [ "authority", "method", "evidence", "event time", "knowledge time" ] }, { "id": "position-and-frame-q03", "text": "What may an agent decide or do once the location of a norepinephrine is known, and what must it refuse?", "kind": "action", "answer_data": [ "permitted actions", "preconditions", "refusals", "escalation" ] } ] } ] }, { "id": "movement-and-transfer", "name": "Movement and transfer", "description": "How a norepinephrine is carried, installed or relocated.", "findings": [ { "id": "movement-events", "name": "Movement events and constraints", "description": "What counts as a movement, what records it and what limits it.", "questions": [ { "id": "movement-events-q01", "text": "What identifies and describes the movement of a norepinephrine, and in what units or vocabulary?", "kind": "definition", "answer_data": [ "identifiers", "types and classes", "values with units", "explicit unknowns" ] }, { "id": "movement-events-q02", "text": "Who or what asserted this about the movement of a norepinephrine, by which method, and when was it true?", "kind": "provenance", "answer_data": [ "authority", "method", "evidence", "event time", "knowledge time" ] }, { "id": "movement-events-q03", "text": "What may an agent decide or do once the movement of a norepinephrine is known, and what must it refuse?", "kind": "action", "answer_data": [ "permitted actions", "preconditions", "refusals", "escalation" ] } ] } ] } ] }, { "id": "state-and-lifecycle", "name": "State and lifecycle", "description": "The states a norepinephrine passes through and the events that move it between them.", "rationale": "Most decisions about a thing depend on what state it is in now, which is a claim with a time on it, not a property.", "layers": [ { "id": "lifecycle-stages", "name": "Lifecycle stages", "description": "From coming into existence to ceasing to be one of these.", "findings": [ { "id": "stages-and-transitions", "name": "Stages and transitions", "description": "The stages worth naming and what moves a norepinephrine between them.", "questions": [ { "id": "stages-and-transitions-q01", "text": "What identifies and describes the lifecycle of a norepinephrine, and in what units or vocabulary?", "kind": "definition", "answer_data": [ "identifiers", "types and classes", "values with units", "explicit unknowns" ] }, { "id": "stages-and-transitions-q02", "text": "Who or what asserted this about the lifecycle of a norepinephrine, by which method, and when was it true?", "kind": "provenance", "answer_data": [ "authority", "method", "evidence", "event time", "knowledge time" ] }, { "id": "stages-and-transitions-q03", "text": "What may an agent decide or do once the lifecycle of a norepinephrine is known, and what must it refuse?", "kind": "action", "answer_data": [ "permitted actions", "preconditions", "refusals", "escalation" ] } ] } ] }, { "id": "observations-and-status", "name": "Observations and current status", "description": "What is observed about a norepinephrine, how often and by whom.", "findings": [ { "id": "observation-record", "name": "Observation record", "description": "How an observation of a norepinephrine is recorded so that it can be superseded rather than overwritten.", "questions": [ { "id": "observation-record-q01", "text": "What identifies and describes an observation of a norepinephrine, and in what units or vocabulary?", "kind": "definition", "answer_data": [ "identifiers", "types and classes", "values with units", "explicit unknowns" ] }, { "id": "observation-record-q02", "text": "Who or what asserted this about an observation of a norepinephrine, by which method, and when was it true?", "kind": "provenance", "answer_data": [ "authority", "method", "evidence", "event time", "knowledge time" ] }, { "id": "observation-record-q03", "text": "What may an agent decide or do once an observation of a norepinephrine is known, and what must it refuse?", "kind": "action", "answer_data": [ "permitted actions", "preconditions", "refusals", "escalation" ] } ] } ] } ] }, { "id": "use-and-operation", "name": "Use and operation", "description": "What can be done with a norepinephrine and what it takes to do it.", "rationale": "An agent that can recognise a thing but not act on it has only half a model.", "layers": [ { "id": "intended-use", "name": "Intended use and function", "description": "What a norepinephrine is for, and what it is used for anyway.", "findings": [ { "id": "function-and-purpose", "name": "Function, purpose and misuse", "description": "The function a norepinephrine performs and the uses that fall outside it.", "questions": [ { "id": "function-and-purpose-q01", "text": "What identifies and describes the use of a norepinephrine, and in what units or vocabulary?", "kind": "definition", "answer_data": [ "identifiers", "types and classes", "values with units", "explicit unknowns" ] }, { "id": "function-and-purpose-q02", "text": "Who or what asserted this about the use of a norepinephrine, by which method, and when was it true?", "kind": "provenance", "answer_data": [ "authority", "method", "evidence", "event time", "knowledge time" ] }, { "id": "function-and-purpose-q03", "text": "What may an agent decide or do once the use of a norepinephrine is known, and what must it refuse?", "kind": "action", "answer_data": [ "permitted actions", "preconditions", "refusals", "escalation" ] } ] } ] }, { "id": "handling-and-procedure", "name": "Handling and procedure", "description": "The steps, skills and tools involved in using a norepinephrine.", "findings": [ { "id": "procedures-and-skills", "name": "Procedures, skills and required tools", "description": "What an agent needs before it can act on a norepinephrine at all.", "questions": [ { "id": "procedures-and-skills-q01", "text": "What identifies and describes handling a norepinephrine, and in what units or vocabulary?", "kind": "definition", "answer_data": [ "identifiers", "types and classes", "values with units", "explicit unknowns" ] }, { "id": "procedures-and-skills-q02", "text": "Who or what asserted this about handling a norepinephrine, by which method, and when was it true?", "kind": "provenance", "answer_data": [ "authority", "method", "evidence", "event time", "knowledge time" ] }, { "id": "procedures-and-skills-q03", "text": "What may an agent decide or do once handling a norepinephrine is known, and what must it refuse?", "kind": "action", "answer_data": [ "permitted actions", "preconditions", "refusals", "escalation" ] } ] } ] }, { "id": "supply-and-consumption", "name": "Supply and consumption", "description": "Quantities, rates and what running out means.", "findings": [ { "id": "consumption-and-stock", "name": "Consumption, stock and replenishment", "description": "How much of a norepinephrine there is and how fast it goes.", "questions": [ { "id": "consumption-and-stock-q01", "text": "What identifies and describes the supply of a norepinephrine, and in what units or vocabulary?", "kind": "definition", "answer_data": [ "identifiers", "types and classes", "values with units", "explicit unknowns" ] }, { "id": "consumption-and-stock-q02", "text": "Who or what asserted this about the supply of a norepinephrine, by which method, and when was it true?", "kind": "provenance", "answer_data": [ "authority", "method", "evidence", "event time", "knowledge time" ] }, { "id": "consumption-and-stock-q03", "text": "What may an agent decide or do once the supply of a norepinephrine is known, and what must it refuse?", "kind": "action", "answer_data": [ "permitted actions", "preconditions", "refusals", "escalation" ] } ] } ] } ] }, { "id": "composition-and-identity", "name": "Composition, grade and chemical identity", "description": "What norepinephrine is made of and how pure the thing in hand is.", "rationale": "Grade decides what a substance may be used for, so a model that records only the name cannot support any decision about use.", "layers": [ { "id": "chemical-identity", "name": "Chemical identity", "description": "Formula, structure and the registry numbers that name it unambiguously.", "findings": [ { "id": "identity-record", "name": "Identity and registry numbers", "description": "What identifies this substance across suppliers and regulators.", "questions": [ { "id": "identity-record-q01", "text": "What formula, structure and registry identifiers name norepinephrine unambiguously?", "kind": "definition" }, { "id": "identity-record-q02", "text": "Which related substances share a name in common use but not an identifier?", "kind": "boundary" } ] } ] }, { "id": "grade-and-impurities", "name": "Grade, purity and impurities", "description": "The specification a batch meets and what else is in it.", "findings": [ { "id": "specification", "name": "Specification and assay", "description": "How purity is stated and measured, and which impurities matter.", "questions": [ { "id": "specification-q01", "text": "What grades of norepinephrine exist, how is purity assayed, and which impurities are limited?", "kind": "measurement" }, { "id": "specification-q02", "text": "Which use requires which grade, and what happens when a lower grade is substituted?", "kind": "action" } ] } ] } ] }, { "id": "properties-and-behaviour", "name": "Properties and behaviour", "description": "How norepinephrine behaves under conditions an agent can measure or change.", "rationale": "Physical constants are the part of a substance model that transfers between contexts, and each needs its unit and its conditions.", "layers": [ { "id": "physical-constants", "name": "Physical constants", "description": "Values that hold for the pure substance, with their conditions.", "findings": [ { "id": "constants-record", "name": "Constants and conditions", "description": "The quantities worth recording and the state they apply in.", "questions": [ { "id": "constants-record-q01", "text": "What are the defining physical constants of norepinephrine, in what units and under what conditions?", "kind": "measurement" }, { "id": "constants-record-q02", "text": "Which of these values change with grade or form rather than being fixed?", "kind": "boundary" } ] } ] }, { "id": "stability-and-reactivity", "name": "Stability and reactivity", "description": "What it reacts with, degrades into, and how it is stored.", "findings": [ { "id": "incompatibilities", "name": "Incompatibilities and degradation", "description": "What must not meet it, and what it becomes over time.", "questions": [ { "id": "incompatibilities-q01", "text": "What is norepinephrine incompatible with, and what does it degrade into under storage?", "kind": "definition" }, { "id": "incompatibilities-q02", "text": "What storage and handling does that require, and who is competent to do it?", "kind": "action" } ] } ] } ] }, { "id": "hazard-and-regulation", "name": "Hazard classification and regulation", "description": "How norepinephrine can harm, and what the law says about holding and moving it.", "rationale": "A substance model without its hazard class and its regulatory identity is unusable in exactly the situations that matter.", "layers": [ { "id": "hazard-class", "name": "Hazard classification", "description": "Classified hazards, exposure limits and protective measures.", "findings": [ { "id": "classified-hazards", "name": "Classified hazards and limits", "description": "The classification, the scheme it belongs to, and the limits set.", "questions": [ { "id": "classified-hazards-q01", "text": "How is norepinephrine classified for hazard, under which scheme, and what exposure limits apply?", "kind": "definition" }, { "id": "classified-hazards-q02", "text": "What protection does handling require, and what must an agent refuse to do without it?", "kind": "action" } ] } ] }, { "id": "regulatory-identity", "name": "Regulatory identity and control", "description": "Registration, restriction and transport rules by jurisdiction.", "findings": [ { "id": "controls", "name": "Controls and jurisdiction", "description": "Where it is restricted and what the restriction attaches to.", "questions": [ { "id": "controls-q01", "text": "Which registrations, restrictions or transport rules cover norepinephrine, and where?", "kind": "provenance" }, { "id": "controls-q02", "text": "Does the control attach to the substance, its concentration, or its intended use?", "kind": "boundary" } ] } ] } ] }, { "id": "provenance-and-evidence", "name": "Provenance, evidence and time", "description": "Where every claim about a norepinephrine came from and when it held.", "rationale": "A claim without a source and a time cannot be superseded, only overwritten, and an agent that overwrites loses the ability to explain itself.", "layers": [ { "id": "source-and-authority", "name": "Source and authority", "description": "Who said it, on what evidence, and how strongly.", "findings": [ { "id": "claim-provenance", "name": "Claim provenance and confidence", "description": "The authority behind each claim about a norepinephrine and how confident it is.", "questions": [ { "id": "claim-provenance-q01", "text": "What identifies and describes a claim about a norepinephrine, and in what units or vocabulary?", "kind": "definition", "answer_data": [ "identifiers", "types and classes", "values with units", "explicit unknowns" ] }, { "id": "claim-provenance-q02", "text": "Who or what asserted this about a claim about a norepinephrine, by which method, and when was it true?", "kind": "provenance", "answer_data": [ "authority", "method", "evidence", "event time", "knowledge time" ] }, { "id": "claim-provenance-q03", "text": "What may an agent decide or do once a claim about a norepinephrine is known, and what must it refuse?", "kind": "action", "answer_data": [ "permitted actions", "preconditions", "refusals", "escalation" ] } ] } ] }, { "id": "time-and-versions", "name": "Time, versions and supersession", "description": "When a claim was true, when it was learnt, and what replaced it.", "findings": [ { "id": "validity-and-supersession", "name": "Validity period and supersession", "description": "How an old claim about a norepinephrine is retired without being erased.", "questions": [ { "id": "validity-and-supersession-q01", "text": "What identifies and describes the validity of a claim about a norepinephrine, and in what units or vocabulary?", "kind": "definition", "answer_data": [ "identifiers", "types and classes", "values with units", "explicit unknowns" ] }, { "id": "validity-and-supersession-q02", "text": "Who or what asserted this about the validity of a claim about a norepinephrine, by which method, and when was it true?", "kind": "provenance", "answer_data": [ "authority", "method", "evidence", "event time", "knowledge time" ] }, { "id": "validity-and-supersession-q03", "text": "What may an agent decide or do once the validity of a claim about a norepinephrine is known, and what must it refuse?", "kind": "action", "answer_data": [ "permitted actions", "preconditions", "refusals", "escalation" ] } ] } ] } ] } ] }, "statistics": { "bundles": 9, "layers": 20, "findings": 22, "questions": 60 } } } }